Research programme: natural killer cell cancer therapies - NantKwest

Drug Profile

Research programme: natural killer cell cancer therapies - NantKwest

Alternative Names: CD19 target activated natural killer cellular therapy - NantKwest; CD19.taNK therapy - NantKwest; CS1 target activated natural killer cellular therapy- NantKwest; CS1.taNK therapy - NantKwest; CST 102; CST 103; haNK cells; HER2.tank; High-affinity natural killer cells; taNK cells; Target-activated natural killer cells; ZRx 102; ZRx 103; ZRx 104

Latest Information Update: 27 Jan 2017

Price : $50

At a glance

  • Originator ZelleRx
  • Developer NantKwest
  • Class Cell therapies
  • Mechanism of Action Cell death stimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Brain cancer; Breast cancer; Colorectal cancer; Lymphoma; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 23 Jan 2017 The US FDA approves IND application for haNK cell therapy in Solid tumours
  • 23 Jan 2017 NantKwest plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Monotherapy) in USA
  • 12 Dec 2016 Pharmacodynamics data from a preclinical trial in Breast cancer released by NantKwest
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top